DelveInsight “PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the PD-1 Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the PD-1 Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the PD-1 Non-Small Cell Lung Cancer Market Share @ PD-1 Non-Small Cell Lung Cancer Market Outlook
Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Market Report
Stay ahead in the PD-1 Non-Small Cell Lung Cancer Therapeutics Market with DelveInsight’s Strategic Report @ PD-1 Non-Small Cell Lung Cancer Treatment Market Size
PD-1 Non-Small Cell Lung Cancer Epidemiology Segmentation in the 7MM
The epidemiology section of PD-1 Non-Small Cell Lung Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving PD-1 Non-Small Cell Lung Cancer Epidemiology trends @ PD-1 Non-Small Cell Lung Cancer Prevalence
PD-1 Non-small Cell Lung Cancer Marketed Drugs
KEYTRUDA is a PD-1-blocking antibody. It is mainly used for advanced cancers that have spread to other body parts or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high protein levels known as PD-(L)1. In NSCLC, it is in combination with pemetrexed and platinum chemotherapy as first-line treatment of patients with metastatic non squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. Combining with carboplatin and either paclitaxel or paclitaxel protein-bound as first-line treatment of patients with metastatic squamous NSCLC. The dominance of KEYTRUDA in the oncology drugs market highlights the success of Merck’s commercial tactics and the direction of its R&D department. The department is also tasked with evaluating the efficacy of this blockbuster in combination with drugs such as vibostolimab, quavonlimab, and faveselimab.
OPDIVO by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. It is a prescription medicine used to treat people with unresectable or metastatic melanoma, metastatic NSCLC, SCLC, advanced renal cell carcinoma, classical Hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer and hepatocellular carcinoma.
PD-1 Non-small Cell Lung Cancer Emerging Drugs
Sugemalimab is an investigational anti-PD-(L)1 monoclonal antibody discovered by CStone. In December 2022, EQRx announced the acceptance of the Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for sugemalimab in metastatic NSCLC. The application was based on data from the pivotal Phase III GEMSTONE-302 trial, which assessed sugemalimab in combination with chemotherapy as the first-line treatment of metastatic NSCLC.In May 2023, CStone announced that they would regain rights for developing and commercializing sugemalimab outside Greater China upon terminating the license agreement for sugemalimab between CStone and EQRx. Upon transition completion, CStone will lead the regulatory process for sugemalimab MAA reviews by the EMA and the UK MHRA.
Datopotamab Deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, Datopotamab Deruxtecan is one of five lead ADCs in the oncology pipeline of Daiichi Sankyo and one of the most advanced programs in AstraZeneca’s ADC scientific platform.
To learn more about PD-1 Non-Small Cell Lung Cancer treatment guidelines, visit @ PD-1 Non-Small Cell Lung Cancer Treatment Market Landscape
PD-1 Non-small Cell Lung Cancer Drugs Market Insights
Checkpoint inhibitors targeting PD-(L)1 have emerged as dominant forces in the immunotherapy landscape for cancer treatment, with ten PD-(L)1 inhibitors approved, comprising seven PD-1 and three PD-L1 inhibitors in the United States. Their efficacy has been notable across various solid tumors, with KEYTRUDA being a standout among these agents, approved for a remarkable twenty indications and holding a significant market presence for several years. However, recent concerns over adverse events have prompted a shift towards combination approaches aimed at enhancing both efficacy and safety. This strategy involves combining PD-(L)1 inhibitors with other checkpoint inhibitors such as CTLA-4, TIGIT, and LAG-3, as well as exploring novel targets like TROP-2. Due to its numerous indication approvals, which led to a comprehensive FDA label and widespread use across a number of indications, PD-1 exceeds the sales of PD-L1 in the 7MM market. Despite their potential, immune checkpoint inhibitors face challenges, including immune-related side effects and high costs, highlighting the critical need for reliable biomarkers to identify patients who would benefit most from these treatments.
PD-1 Non-Small Cell Lung Cancer Market Outlook
Chemotherapy was used as the standard of care in the advanced and metastatic stages until the first ICI ‘KEYTRUDA’ got approved in 2015 as a second-line treatment option for such advanced patients; a similar path was followed by TECENTRIQ who entered the market in 2016. These therapies entered the first-line domain after 2016 and expanded their labels by expanding the targetable pool. In 2020, OPDIVO + ipilimumab was approved as a 1L treatment for patients with metastatic NSCLC. In the United States, OPDIVO sales are largely fueled by continued demand growth across indications such as NSCLC, melanoma, renal cancer, and upper gastrointestinal cancers. Chinese companies are trying to enter the US and EU markets, especially the EU markets where TIZVENI-approved in 2024 and sugemalimab is currently under review..
Major PD-1 Non-Small Cell Lung Cancer Companies
Regeneron Pharmaceuticals, Sanofi, Bavarian Nordic, Sichuan University, Chengdu MedGenCell Co. Ltd., Merck Sharp & Dohme LLC, Dynavax Technologies Corporation, BeiGene, Tesaro Inc., Bristol-Myers Squibb, and others.
Learn more about the FDA-approved drugs for PD-1 Non-Small Cell Lung Cancer @ Drugs for PD-1 Non-Small Cell Lung Cancer Treatment
Scope of the PD-1 Non-Small Cell Lung Cancer Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• PD-1 Non-Small Cell Lung Cancer Companies- Regeneron Pharmaceuticals, Sanofi, Bavarian Nordic, Sichuan University, Chengdu MedGenCell Co. Ltd., Merck Sharp & Dohme LLC, Dynavax Technologies Corporation, BeiGene, Tesaro Inc., Bristol-Myers Squibb, and others.
• PD-1 Non-Small Cell Lung Cancer Pipeline Therapies- AZD2936, Pembrolizumab 200 mg, Cisplatin, Carboplatin, Gemcitabine, Gotistobart, Docetaxel, PF-06801591 and others.
• PD-1 Non-Small Cell Lung Cancer Market Dynamics: PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers
• PD-1 Non-Small Cell Lung Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives
Table of Content
1. Key Insights
2. PD-1 Non-Small Cell Lung Cancer Executive Summary
3. PD-1 Non-Small Cell Lung Cancer Competitive Intelligence Analysis
4. PD-1 Non-Small Cell Lung Cancer: Market Overview at a Glance
5. PD-1 Non-Small Cell Lung Cancer: Disease Background and Overview
6. Patient Journey
7. PD-1 Non-Small Cell Lung Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. PD-1 Non-Small Cell Lung Cancer Unmet Needs
10. Key Endpoints of PD-1 Non-Small Cell Lung Cancer Treatment
11. PD-1 Non-Small Cell Lung Cancer Marketed Products
12. PD-1 Non-Small Cell Lung Cancer Emerging Therapies
13. PD-1 Non-Small Cell Lung Cancer: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: PD-1 Non-Small Cell Lung Cancer Market Outlook
16. Access and Reimbursement Overview of PD-1 Non-Small Cell Lung Cancer
17. KOL Views
18. PD-1 Non-Small Cell Lung Cancer Market Drivers
19. PD-1 Non-Small Cell Lung Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
